In addition, there is currently an ongoing clinical trial (NCT02897765) combining a personalized vaccine (NEO-PV-01) with anti-PD-1 in patients with advanced cancers including melanoma, NSCLC and bladder cancer. Here, PDCD1 is linked to non-small cell lung carcinoma.